A new University of Minnesota startup company is aiming to commercialize two revolutionary cardiovascular-related products.

Vascudyne, launched by the University of Minnesota Technology Commercialization department, plans to develop bioengineered tissue using research by Dr. Robert Tranquillo.

“We are excited about the prospects of this material [becoming] a clinical reality with its commercialization by Vascudyne,” said Dr. Tranquillo, Stem Cell Institute.

The products offered by Vascudyne have regenerative capabilities which are unmatched in the market today.

“Professor Tranquillo’s innovative cardiovascular tissue platform is well positioned to help the field take this important step into the future,” said Luke Brewster in an interview with Twin Cities Business.